Erin T. Welsh, MA , 2025-04-28 13:15:00
April 28, 2025
8 min watch
Compared with men, women develop HF when they are older and have a higher HF with preserved ejection fraction risk and, to prevent and manage HF, women should be screened for key comorbidities and use certain treatments more than others.
Stephanie Poon, MD, MSc, FRCPC, associate professor at the University of Toronto and medical director of the Heart Function Clinic at Sunnybrook Health Sciences Centre, noted that despite significant progress in understanding sex differences in HF, many questions remain, so it is important for women to be adequately represented in HF trials to continue closing gaps and improving care.
“HF tends to present at a more advanced stage in women, but women still represent half of all incident HF cases. We also know that more than half of all people who die from HF are women,” Poon told Healio. “Despite this, women have been significantly underrepresented in HF clinical trials, accounting for only 20% to 25% of study participants.”
Reference:
- Poon S, et al. Heart failure and preserved ejection fraction in older women: The role of prevention, screening and management. Presented at: American College of Cardiology Scientific Session; March 29-31, 2025; Chicago (hybrid meeting).
For more information:
Stephanie Poon, MD, MSc, FRCPC, can be reached at stephanie.poon@sunnybrook.ca.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
Poon reports receiving consultant fees and honoraria from Bayer, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline and Novo Nordisk; and serves on the speakers bureau for Abbott.
